Peringatan Keamanan

Symptoms of overdose include nausea and vomiting, anorexia, myelosuppression; and nephrotoxicity.

Streptozocin

DB00428

small molecule approved investigational

Deskripsi

An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.

Struktur Molekul 2D

Berat 265.222
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 5-15 minutes
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Poor oral absorption (17-25%)

Metabolisme

Primarily hepatic

Rute Eliminasi

As much as 20% of the drug (or metabolites containing an N-nitrosourea group) is metabolized and/or excreted by the kidney.

Interaksi Obat

528 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Streptozocin.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Streptozocin.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Streptozocin.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Streptozocin.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Streptozocin.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Streptozocin.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Streptozocin.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Streptozocin.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Streptozocin.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Streptozocin.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Streptozocin.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Streptozocin.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Streptozocin.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Streptozocin.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Streptozocin.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Streptozocin.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Streptozocin.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Streptozocin.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Streptozocin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Streptozocin.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Streptozocin.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Streptozocin.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Streptozocin.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Streptozocin.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Streptozocin.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Streptozocin.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Streptozocin.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Streptozocin.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Streptozocin.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Streptozocin.
Cladribine Streptozocin may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Streptozocin.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Streptozocin.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Streptozocin.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Streptozocin.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Streptozocin.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Streptozocin.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Streptozocin.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Streptozocin.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Streptozocin.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Streptozocin.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Streptozocin.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Streptozocin.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Streptozocin.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Streptozocin.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Streptozocin.
Trifluridine The risk or severity of adverse effects can be increased when Streptozocin is combined with Trifluridine.
Gemcitabine The risk or severity of adverse effects can be increased when Streptozocin is combined with Gemcitabine.
Betamethasone The risk or severity of adverse effects can be increased when Streptozocin is combined with Betamethasone.
Teniposide The risk or severity of adverse effects can be increased when Streptozocin is combined with Teniposide.
Epirubicin The risk or severity of adverse effects can be increased when Streptozocin is combined with Epirubicin.
Chloramphenicol The risk or severity of adverse effects can be increased when Streptozocin is combined with Chloramphenicol.
Lenalidomide The risk or severity of adverse effects can be increased when Streptozocin is combined with Lenalidomide.
Altretamine The risk or severity of adverse effects can be increased when Streptozocin is combined with Altretamine.
Zidovudine The risk or severity of adverse effects can be increased when Streptozocin is combined with Zidovudine.
Cisplatin The risk or severity of adverse effects can be increased when Streptozocin is combined with Cisplatin.
Oxaliplatin The risk or severity of adverse effects can be increased when Streptozocin is combined with Oxaliplatin.
Cyclophosphamide The risk or severity of adverse effects can be increased when Streptozocin is combined with Cyclophosphamide.
Fluorouracil The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluorouracil.
Propylthiouracil The risk or severity of adverse effects can be increased when Streptozocin is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Streptozocin is combined with Pentostatin.
Methotrexate The risk or severity of adverse effects can be increased when Streptozocin is combined with Methotrexate.
Vinblastine The risk or severity of adverse effects can be increased when Streptozocin is combined with Vinblastine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluocinolone acetonide.
Linezolid The risk or severity of adverse effects can be increased when Streptozocin is combined with Linezolid.
Imatinib The risk or severity of adverse effects can be increased when Streptozocin is combined with Imatinib.
Triamcinolone The risk or severity of adverse effects can be increased when Streptozocin is combined with Triamcinolone.
Clofarabine The risk or severity of adverse effects can be increased when Streptozocin is combined with Clofarabine.
Prednisone The risk or severity of adverse effects can be increased when Streptozocin is combined with Prednisone.
Pemetrexed The risk or severity of adverse effects can be increased when Streptozocin is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Streptozocin is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Streptozocin is combined with Mycophenolate mofetil.
Daunorubicin The risk or severity of adverse effects can be increased when Streptozocin is combined with Daunorubicin.
Irinotecan The risk or severity of adverse effects can be increased when Streptozocin is combined with Irinotecan.
Methimazole The risk or severity of adverse effects can be increased when Streptozocin is combined with Methimazole.
Etoposide The risk or severity of adverse effects can be increased when Streptozocin is combined with Etoposide.
Sulfasalazine The risk or severity of adverse effects can be increased when Streptozocin is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Streptozocin is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Streptozocin is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Streptozocin is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Streptozocin is combined with Prednisolone.
Mechlorethamine The risk or severity of adverse effects can be increased when Streptozocin is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Streptozocin is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Streptozocin is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Streptozocin is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Streptozocin is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Streptozocin is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Streptozocin is combined with Azathioprine.
Hydroxyurea The risk or severity of adverse effects can be increased when Streptozocin is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Streptozocin is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Streptozocin is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Streptozocin is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Streptozocin is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Streptozocin is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Streptozocin is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Streptozocin is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Streptozocin is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Streptozocin is combined with Capecitabine.
Trilostane The risk or severity of adverse effects can be increased when Streptozocin is combined with Trilostane.

Target Protein

O-GlcNAcase BT_4395
DNA
Solute carrier family 2, facilitated glucose transporter member 2 SLC2A2
Protein O-GlcNAcase OGA

Referensi & Sumber

Artikel (PubMed)
  • PMID: 11459269
    Brentjens R, Saltz L: Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am. 2001 Jun;81(3):527-42.
  • PMID: 9421374
    Wang Z, Gleichmann H: GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes. 1998 Jan;47(1):50-6.
  • PMID: 7926307
    Schnedl WJ, Ferber S, Johnson JH, Newgard CB: STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes. 1994 Nov;43(11):1326-33.
  • PMID: 13841501
    VAVRA JJ, DEBOER C, DIETZ A, HANKA LJ, SOKOLSKI WT: Streptozotocin, a new antibacterial antibiotic. Antibiot Annu. 1959-1960;7:230-5.
  • PMID: 4170654
    Mansford KR, Opie L: Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet. 1968 Mar 30;1(7544):670-1.
Link

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Zanosar
    Powder, for solution • 100 mg/1mL • Intravenous • US • Approved
  • Zanosar
    Powder, for solution • 1 g/10mL • Intravenous • US
  • Zanosar Sterile Powder
    Powder, for solution • 1 g / vial • Intravenous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul